ACLX
Price
$75.43
Change
-$6.60 (-8.05%)
Updated
Dec 18 closing price
91 days until earnings call
ZYME
Price
$12.80
Change
+$0.06 (+0.47%)
Updated
Dec 19, 10:34 AM (EDT)
Ad is loading...

ACLX vs ZYME

Header iconACLX vs ZYME Comparison
Open Charts ACLX vs ZYMEBanner chart's image
Arcellx
Price$75.43
Change-$6.60 (-8.05%)
Volume$1.23M
CapitalizationN/A
Zymeworks
Price$12.80
Change+$0.06 (+0.47%)
Volume$500
CapitalizationN/A
ACLX vs ZYME Comparison Chart
Loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACLX vs. ZYME commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Hold and ZYME is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ACLX: $75.43 vs. ZYME: $12.74)
Brand notoriety: ACLX and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 208% vs. ZYME: 108%
Market capitalization -- ACLX: $4.44B vs. ZYME: $920.89M
ACLX [@Biotechnology] is valued at $4.44B. ZYME’s [@Biotechnology] market capitalization is $920.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than ACLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 4 bullish TA indicator(s).

  • ACLX’s TA Score: 3 bullish, 6 bearish.
  • ZYME’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than ACLX.

Price Growth

ACLX (@Biotechnology) experienced а -13.28% price change this week, while ZYME (@Biotechnology) price change was -2.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.34%. For the same industry, the average monthly price growth was -2.44%, and the average quarterly price growth was +0.79%.

Reported Earning Dates

ACLX is expected to report earnings on Mar 20, 2025.

ZYME is expected to report earnings on May 08, 2023.

Industries' Descriptions

@Biotechnology (-4.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACLX($4.44B) has a higher market cap than ZYME($921M). ACLX YTD gains are higher at: 35.910 vs. ZYME (22.618). ACLX has higher annual earnings (EBITDA): -33.12M vs. ZYME (-110.13M). ACLX has more cash in the bank: 574M vs. ZYME (297M). ZYME has less debt than ACLX: ZYME (20.2M) vs ACLX (65.3M). ACLX has higher revenues than ZYME: ACLX (156M) vs ZYME (62.2M).
ACLXZYMEACLX / ZYME
Capitalization4.44B921M482%
EBITDA-33.12M-110.13M30%
Gain YTD35.91022.618159%
P/E RatioN/AN/A-
Revenue156M62.2M251%
Total Cash574M297M193%
Total Debt65.3M20.2M323%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
71
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACLXZYME
RSI
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TINT31.20N/A
N/A
ProShares Smart Materials ETF
PQDI19.07-0.05
-0.24%
Principal Spectrum Tax-Adv Dvd Actv ETF
XSEP38.77-0.35
-0.91%
FT Vest U.S. Eq Enh & ModBufETF-Sep
HDEF24.15-0.59
-2.38%
Xtrackers MSCI EAFE High Div Yld Eq ETF
ETCG13.75-1.63
-10.60%
Grayscale Ethereum Classic Trust (ETC)

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
-8.04%
DNLI - ACLX
49%
Loosely correlated
-7.71%
BEAM - ACLX
49%
Loosely correlated
-7.45%
RCKT - ACLX
48%
Loosely correlated
-1.51%
CRSP - ACLX
47%
Loosely correlated
-8.00%
RCUS - ACLX
47%
Loosely correlated
-5.66%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with BEAM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-4.71%
BEAM - ZYME
45%
Loosely correlated
-7.45%
NKTX - ZYME
42%
Loosely correlated
-4.41%
VRDN - ZYME
42%
Loosely correlated
-9.08%
ACLX - ZYME
41%
Loosely correlated
-8.04%
ALLO - ZYME
41%
Loosely correlated
-7.97%
More